JP2024532854A5 - - Google Patents

Info

Publication number
JP2024532854A5
JP2024532854A5 JP2024510304A JP2024510304A JP2024532854A5 JP 2024532854 A5 JP2024532854 A5 JP 2024532854A5 JP 2024510304 A JP2024510304 A JP 2024510304A JP 2024510304 A JP2024510304 A JP 2024510304A JP 2024532854 A5 JP2024532854 A5 JP 2024532854A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
use according
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024510304A
Other languages
English (en)
Japanese (ja)
Other versions
JP7839265B2 (ja
JP2024532854A (ja
Filing date
Publication date
Priority claimed from CN202110668896.0A external-priority patent/CN113248501B/zh
Application filed filed Critical
Publication of JP2024532854A publication Critical patent/JP2024532854A/ja
Publication of JP2024532854A5 publication Critical patent/JP2024532854A5/ja
Application granted granted Critical
Publication of JP7839265B2 publication Critical patent/JP7839265B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024510304A 2021-06-17 2022-06-17 Ｃｌｙシリーズ化合物及びその調製方法並びにその調製薬物の用途 Active JP7839265B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110668896.0 2021-06-17
CN202110668896.0A CN113248501B (zh) 2021-06-17 2021-06-17 Cly系列化合物及其制备方法和制备药物的用途
PCT/CN2022/099496 WO2022262854A1 (zh) 2021-06-17 2022-06-17 Cly系列化合物及其制备方法和制备药物的用途

Publications (3)

Publication Number Publication Date
JP2024532854A JP2024532854A (ja) 2024-09-10
JP2024532854A5 true JP2024532854A5 (https=) 2026-01-14
JP7839265B2 JP7839265B2 (ja) 2026-04-01

Family

ID=77188283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510304A Active JP7839265B2 (ja) 2021-06-17 2022-06-17 Ｃｌｙシリーズ化合物及びその調製方法並びにその調製薬物の用途

Country Status (6)

Country Link
US (1) US20240300945A1 (https=)
EP (1) EP4357345A4 (https=)
JP (1) JP7839265B2 (https=)
KR (1) KR20240022602A (https=)
CN (2) CN113248501B (https=)
WO (1) WO2022262854A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
AR132543A1 (es) * 2023-04-28 2025-07-16 Initial Therapeutics Inc Compuestos, composiciones y métodos para la atenuación de la traducción en mamíferos de proteínas c-myc o n-myc de la familia de protooncogenes myc de factores de transcripción bhlh

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572821A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
JP6020396B2 (ja) * 2012-09-12 2016-11-02 大正製薬株式会社 アゾール誘導体を含有する医薬
EP2986599A1 (en) * 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) * 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3442960A1 (en) * 2016-04-12 2019-02-20 Esteve Pharmaceuticals, S.A. Arylamide derivatives having multimodal activity against pain
CN107311996A (zh) * 2016-04-27 2017-11-03 成都贝斯凯瑞生物科技有限公司 一种酰胺化合物及其应用
CN110546149B (zh) * 2017-04-21 2022-11-11 深圳信立泰药业股份有限公司 作为pcsk9抑制剂的哌啶类化合物
JP7191927B2 (ja) * 2017-07-12 2022-12-19 サムソン クリニカル プロプライエタリー リミテッド 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP2020528058A (ja) * 2017-07-21 2020-09-17 アイカーン スクール オブ メディスン アット マウント シナイ Ｓｕｍｏアクチベーターとしてのベンゾチアゾールおよびピリドチアゾール化合物
CA3093469A1 (en) * 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
BR112021013807A2 (pt) * 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) * 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN113387945A (zh) * 2020-03-11 2021-09-14 陈敏 化合物ptm-3、ptm-4及其制备方法和制备药物的用途
CN112094268B (zh) * 2020-11-09 2021-02-09 南京韦尔优众医药有限公司 化合物wez系列及其制备方法和制备药物的用途
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途

Similar Documents

Publication Publication Date Title
ES2557453T3 (es) Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog
CN100406006C (zh) 皮肤色素沉着的治疗剂
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
ES2562775T3 (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi) pirimidina y métodos para su uso
KR102477187B1 (ko) 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용
JP2008540549A5 (https=)
JP2024532854A5 (https=)
WO2023011301A1 (zh) 一种具有高口服生物利用度的jak抑制剂
SK14762003A3 (sk) Kožou prestupujúci prípravok obsahujúci selektívne inhibujúcu cyklooxygenázu-2 a jednosýtny alkohol
US20230134672A1 (en) Ketorolaco derivative, pharmaceutical composition and preparation method therefor and use thereof
CN114008028A (zh) 抑制癌细胞生长的嘧啶衍生物及其医药用途
CN113402543B (zh) 丁苯酞开环衍生物及其制备方法和用途
CN104530054B (zh) 盐酸优克那非的多晶型物及其制备方法
US10736884B2 (en) Compositions and methods of Rit1 inhibition
WO2018031988A1 (en) Biaryl compositions and methods for modulating a kinase cascade
CN105669589B (zh) 2‑(5‑酰基噻唑‑2‑亚氨基)‑4‑噻唑啉酮及其制备方法与应用
CN102796121B (zh) 3-芳基-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类衍生物及其应用
JP6069485B2 (ja) （ｌ、２、３−トリアゾリル）スルホニル誘導体
WO2023274258A1 (zh) 一种杂原子取代的芳香类化合物及其制备方法和用途
JP2024524986A5 (https=)
CN121108070A (zh) 双苯基噁二唑类化合物或其盐、其制备方法及应用
HK40097518A (zh) 氘化的dhodh抑制剂
CN119528827A (zh) 一种酞嗪酮类化合物及其制备方法、药物组合物及用途
CN105541752B (zh) 2‑(4‑氧代噻唑啉‑2‑亚氨基)噻唑‑4‑乙酸衍生物的制备方法与应用
JP2003113084A (ja) 肺高血圧症の治療及び／または予防薬